618 related articles for article (PubMed ID: 26289212)
1. Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis - a critical review.
Singh J; Garg T; Rath G; Goyal AK
Drug Deliv; 2016 Jun; 23(5):1676-98. PubMed ID: 26289212
[TBL] [Abstract][Full Text] [Related]
2. Current Nanotechnological Approaches for an Effective Delivery of Bioactive Drug Molecules to Overcome Drug Resistance Tuberculosis.
Garg T; Rath G; Murthy RR; Gupta UD; Vatsala PG; Goyal AK
Curr Pharm Des; 2015; 21(22):3076-89. PubMed ID: 26027577
[TBL] [Abstract][Full Text] [Related]
3. Recent therapeutic approaches for the management of tuberculosis: Challenges and opportunities.
Patil K; Bagade S; Bonde S; Sharma S; Saraogi G
Biomed Pharmacother; 2018 Mar; 99():735-745. PubMed ID: 29710471
[TBL] [Abstract][Full Text] [Related]
4. Nanocarrier-based interventions for the management of MDR/XDR-TB.
Mustafa S; Pai RS; Singh G; Kusum Devi V
J Drug Target; 2015 May; 23(4):287-304. PubMed ID: 25766078
[TBL] [Abstract][Full Text] [Related]
5. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
6. Nanostructured drug delivery for better management of tuberculosis.
Kaur IP; Singh H
J Control Release; 2014 Jun; 184():36-50. PubMed ID: 24732260
[TBL] [Abstract][Full Text] [Related]
7. Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis.
Kaur M; Garg T; Rath G; Goyal AK
Crit Rev Ther Drug Carrier Syst; 2014; 31(1):49-88. PubMed ID: 24579767
[TBL] [Abstract][Full Text] [Related]
8. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects.
Yew WW
Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001
[TBL] [Abstract][Full Text] [Related]
9. Emerging technologies for monitoring drug-resistant tuberculosis at the point-of-care.
Mani V; Wang S; Inci F; De Libero G; Singhal A; Demirci U
Adv Drug Deliv Rev; 2014 Nov; 78():105-17. PubMed ID: 24882226
[TBL] [Abstract][Full Text] [Related]
10. Nano-antimicrobials: A New Paradigm for Combating Mycobacterial Resistance.
Minakshi P; Ghosh M; Brar B; Kumar R; Lambe UP; Ranjan K; Manoj J; Prasad G
Curr Pharm Des; 2019; 25(13):1554-1579. PubMed ID: 31218956
[TBL] [Abstract][Full Text] [Related]
11. Selective drug deposition in lungs through pulmonary drug delivery system for effective management of drug-resistant TB.
Sankhe K; Khan T; Bhavsar C; Momin M; Omri A
Expert Opin Drug Deliv; 2019 May; 16(5):525-538. PubMed ID: 31007100
[TBL] [Abstract][Full Text] [Related]
12. Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012.
Chang KC; Yew WW
Respirology; 2013 Jan; 18(1):8-21. PubMed ID: 22943408
[TBL] [Abstract][Full Text] [Related]
13. Management of multidrug resistant tuberculosis.
Daley CL; Caminero JA
Semin Respir Crit Care Med; 2013 Feb; 34(1):44-59. PubMed ID: 23460005
[TBL] [Abstract][Full Text] [Related]
14. Advances in nanotechnology for diagnosis and treatment of tuberculosis.
Banyal S; Malik P; Tuli HS; Mukherjee TK
Curr Opin Pulm Med; 2013 May; 19(3):289-97. PubMed ID: 23429097
[TBL] [Abstract][Full Text] [Related]
15. Second-line drug susceptibilities of multidrug-resistant tuberculosis strains isolated in Thailand: an update.
Chaiprasert A; Srimuang S; Tingtoy N; Makhao N; Sirirudeeporn P; Tomnongdee N; Theankeaw O; Charoensook S; Leechawengwongs M; Prammananan T
Int J Tuberc Lung Dis; 2014 Aug; 18(8):961-3. PubMed ID: 25199012
[TBL] [Abstract][Full Text] [Related]
16. Extensively drug-resistant tuberculosis: new strains, new challenges.
Banerjee R; Schecter GF; Flood J; Porco TC
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):713-24. PubMed ID: 18847407
[TBL] [Abstract][Full Text] [Related]
17. Micro-nanoemulsion and nanoparticle-assisted drug delivery against drug-resistant tuberculosis: recent developments.
Suman SK; Chandrasekaran N; Priya Doss CG
Clin Microbiol Rev; 2023 Dec; 36(4):e0008823. PubMed ID: 38032192
[TBL] [Abstract][Full Text] [Related]
18. New treatment options for multidrug-resistant tuberculosis.
Field SK; Fisher D; Jarand JM; Cowie RL
Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
[TBL] [Abstract][Full Text] [Related]
19. Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa.
Streicher EM; Müller B; Chihota V; Mlambo C; Tait M; Pillay M; Trollip A; Hoek KG; Sirgel FA; Gey van Pittius NC; van Helden PD; Victor TC; Warren RM
Infect Genet Evol; 2012 Jun; 12(4):686-94. PubMed ID: 21839855
[TBL] [Abstract][Full Text] [Related]
20. Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis.
Heyckendorf J; Olaru ID; Ruhwald M; Lange C
Am J Respir Crit Care Med; 2014 Aug; 190(4):374-83. PubMed ID: 24941306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
